NanoViricides Signs Agreement with Viroclinics Biosciences BV for Testing of Various NanoViricides Against Specific Viruses of Current Concern
WEST HAVEN, CONNECTICUT -- Tuesday, February 4th, 2014 -- NanoViricides, Inc. (NYSE MKT: NNVC) reported today that it has signed a "confidential disclosure agreement" ("CDA") with Viroclinics Biosciences, BV ("Viroclinics"), a spinoff of the Department of Viroscience at the Erasmus Medical Centre ("Erasmus") in Rotterdam, the Netherlands. The agreement will allow the scientists at Viroclinics to develop a specific proposal for the testing of different nanoviricides® , such as FluCide™, against viruses of mutual interest to both organizations.
Viroclinics is a virology contract research organization serving the biopharmaceutical community(http://www.viroclinics.com/en-GB/). Viroclinics provides preclinical as well as clinical development services for vaccines and antivirals. The ongoing, intimate interaction between scientists at Erasmus and Viroclinics staff yields a strong, flourishing platform to create and implement assays at the forefront of viroscience. Viroclinics participated in the discovery and characterization of the Middle East Respiratory Syndrome (MERS) Coronavirus in 2013 and SARS Coronavirus in 2003, attesting to its leadership position in the field.
NanoViricides, Inc. anticipates that we will be able to test and develop our drug candidates against influenzas, dengue, MERS Coronavirus, as well as rabies, with the help of Viroclinics. In particular, NanoViricides is interested in the testing of its lead broad-spectrum anti-influenza drug candidate FluCide against various influenza A strains including the highly lethal H5N1 and H7N9 viruses that pose a strong global public health threat.
Testing of nanoviricides antiviral drug candidates will be performed in a BSL2 or BSL3 facility at Viroclinics, as applicable. These facilities are designed to contain and enable the safe handling of organisms that can pose a significant threat to health. Executives from NanoViricides plan to visit the Rotterdam facility later this month to conclude the final research agreement.
About NanoViricides
NanoViricides, Inc.
(www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to
dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV,
oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could
differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other
written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and
unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially
affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ
materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and
elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of
principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and
obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and
market acceptance of our products.
FDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medical Agency.
Contact:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com